# *Toxoplasma gondii* as a Causal Factor in Schizophrenia: Evidence from Two Large Cohorts

Ariel Israel[1,2]*, Avi Weizman[3], Sarah Israel[4], Joshua Stokar[4], Shai Ashkenazi[5,6], Shlomo Vinker[1], Eli Magen[7], Eugene Merzon[1,5]

**Affiliations:**

[1] Leumit Research Institute, Leumit Health Services; Tel-Aviv, Israel

[2] Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel Aviv University; Tel-Aviv, Israel

[3] Research Unit, Geha Mental Health Center, Petach Tikva, Israel.

[4] Department of Infectious Diseases and Department of Internal Medicine, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem Israel

[5] Adelson School of Medicine, Ariel University; Ariel, Israel.

[6] Department of Infectious Diseases, Schneider Children's Medical Center, Petah-Tikva, Israel

[7] Medicine A Department, Assuta Ashdod University Medical Center, Ben Gurion University of the Negev; Beer Sheva, Israel

*Corresponding author. Email: aisrael@leumit.co.il.

**Background**: Schizophrenia (SCZ) is a debilitating psychiatric disorder with a complex and poorly understood etiology. Numerous studies have reported a high prevalence of *Toxoplasma gondii*-specific immunoglobulins in SCZ patients, indicating past infection, yet the clinical significance of this association remains unclear.

**Methods**: We investigated the impact of medication purchases and past medical conditions on SCZ risk in two large cohorts. In a national cohort, we compared 3,273 individuals diagnosed with SCZ to 32,730 matched controls, adjusting for gender, age, ethnicity, socioeconomic status, and year of enrollment. Key findings were validated prospectively on the U.S. TriNetX collaborative network, which includes over 117 million individuals.

**Results**: In both cohorts, individuals who used atovaquone had a significantly lower risk of developing SCZ over the next decade (adjusted odds ratio = 0.26 in the national cohort; hazard ratio = 0.29 in the TriNetX cohort, both $P < 0.001$). A similar reduction in SCZ risk was observed with clindamycin use, consistent with the known efficacy of both atovaquone and clindamycin against *T. gondii*.

**Discussion**: Based on new epidemiological associations identified by this study, we propose a novel hypothesis for SCZ pathogenesis, in which persistent *T. gondii* colonization in the microbiome, combined with prolonged dissemination into the central nervous system due to an impaired immune response, liver function, and/or alterations in the skin microbiome, may contribute to SCZ development in genetically susceptible individuals.

**Conclusion**: Individuals who received medications known to target *T. gondii* had significantly lower SCZ risk, suggesting a causative role for this pathogen and highlighting potential preventive or therapeutic roles for these medications in SCZ. The observed associations provide new insights into the mechanisms linking *T. gondii* to SCZ, opening novel avenues for research and intervention strategies.

Schizophrenia (SCZ) is a chronic and debilitating psychiatric disorder that affects approximately 1% of the global population[1]. It is characterized by a range of symptoms, including delusions, hallucinations, disorganized thinking, and cognitive impairments[2]. The onset of SCZ typically occurs in late adolescence or early adulthood[3], and the disorder can significantly impair an individual's social, occupational, and personal functioning[4].

Current treatments for SCZ primarily include antipsychotic medications and psychosocial interventions. Antipsychotic drugs, which target dopamine and other neurotransmitter systems[5], can alleviate positive symptoms such as hallucinations and delusions but are less effective in treating negative symptoms and cognitive deficits[6]. Moreover, these medications are often associated with significant side effects, leading to challenges in long-term adherence[7].

The etiology of SCZ remains poorly understood, with a complex interplay of genetic and environmental factors contributing to its development. Genetic studies have identified numerous risk alleles associated with SCZ [8,9], yet these genetic factors account for only a portion of the disease's heritability[10]. Environmental factors, such as prior infection with *Toxoplasma gondii*[12], urban upbringing[11], smoking[13] and particularly cannabis use[14], have also been implicated in increasing the risk of SCZ [15]. Moreover, several studies suggest that infections and immune responses during critical periods of brain development may contribute to SCZ risk.[16–18]. This multifactorial nature highlights the need to explore both biological and environmental factors in the disorder's pathogenesis. While strong evidence links *T. gondii* to SCZ, the causal relationship remains debated, and further research is necessary to determine whether anti-toxoplasmosis treatments could prevent or mitigate SCZ symptoms.

In this study, we leveraged EHRs from a national health system to investigate whether individuals who developed SCZ over the past two decades exhibited distinct patterns of past medical treatments or medical conditions compared to matched controls. Specifically, if *T. gondii*

is a causal agent for SCZ, we would expect treatments known to eradicate the parasite to be associated with a reduced SCZ incidence. Additionally, using a systematic approach, we sought to identify all significant associations between past medication use, prior diagnoses, and laboratory results to gain deeper insights into risk and protective factors contributing to SCZ development.

# Methods

## Study design

The first stage of this research was conducted as a retrospective cohort study in Leumit Health Services (LHS), one of the four national health providers in Israel, providing comprehensive healthcare services to approximately 730,000 members. All Israeli citizens are entitled for comprehensive health insurance and receive a standardized package of health services and medications, as defined by the national "Health Basket" committee. LHS operates a centralized EHR system, with over two decades of meticulously maintained information on patient demographics, medical diagnoses, healthcare encounters, laboratory test results, and records of prescribed and purchased medications. Diagnoses are documented during medical encounters by the treating physicians using the International Classification of Diseases, Ninth Revision (ICD-9). Diagnoses can be marked as chronic when they pertain to a chronic condition, and these can be updated or closed by the treating physicians during subsequent patient encounters. The reliability of these chronic diagnosis records in our registry has been previously validated, demonstrating high accuracy.[56]

Eligibility for inclusion in the study was defined as any past or current LHS member with at least three years of LHS membership between years 2003 and 2024. Data extraction was carried out from the LHS central data warehouse, encompassing diagnoses, results of laboratory

tests, and medication purchases recorded up to December 31, 2024. Data extraction was automated using structured query language (SQL) and Python scripts to retrieve relevant patient information from the LHS data warehouse. Socioeconomic status was determined using geocoded residential addresses and categorized on a scale from 1 (lowest) to 20 (highest) based on the Points Location Intelligence® database, which highly correlates with socioeconomic measures provided by the Israeli Central Bureau of Statistics. Geodemographic classification of patients into the general population, Ultra-Orthodox Jewish population, and Arab population was performed using validated methodologies established in prior studies. Demographic data, laboratory test results, and physical measures, including body mass index (BMI) and blood pressure (BP), were extracted from the EHR. Smoking status and physical measures were documented by treating physicians or nurses during routine medical visits. The most recent available record prior to the index date was used for analysis if available, otherwise the first record after the index date was taken. While annual check-ups are not mandatory for all LHS members, national quality measures ensure regular documentation of smoking status, BMI, BP by healthcare providers.

### Cohort definition

The study cohort consists of eligible SCZ patients diagnosed for the first time between the ages of 13 and 40, alongside a control group matched at a 10:1 ratio, selected from LHS members who had no SCZ diagnosis. To avoid misclassification due to overlapping conditions, individuals with a diagnosis indicative of a cerebrovascular accident were excluded from both groups of the study.

SCZ patients were identified based on the presence of an ICD-10 “F20” coded diagnosis of Schizophrenia recorded in the EHRs. A patient was classified as having SCZ if the diagnosis

was recorded by a psychiatrist or, when recorded by a non-psychiatrist physician in the list of chronic conditions, it had not been subsequently closed and was accompanied by documented purchases of antipsychotic medication for at least five months.

The index date was defined as the earliest recorded SCZ diagnosis in the EHR or the date of the first antipsychotic medication purchase, if the medication was obtained up to one year before the SCZ diagnosis. To ensure that the date of SCZ onset was accurately determined and that medical history prior to disease onset could be extracted from the EHR, we required the first diagnosis of SCZ to occur at least two full years after LHS membership enrollment. Control individuals were matched to SCZ patients based on gender, ethnic group (categorized as ultra-Orthodox, of Arab descent, or the general population), socioeconomic status (SES) category, and year of initial enrollment in LHS. For each SCZ patient, ten control individuals were selected who met these criteria. Among potential control candidates, those with the closest birth date to the SCZ patient were chosen, ensuring that no individual was duplicated within the cohort.

### Data processing

Data were extracted from electronic health records and processed for analysis using scripts developed by the Leumit Research Institute in Python 3.11, utilizing the Pandas library and T-SQL queries. Before analysis, patient data were deidentified, with patient ID numbers replaced by study-specific internal identifiers.

Medication consumption was analyzed based on the purchase records classified according to the medication Anatomical Therapeutic Chemical (ATC) classification and route of administration and covered the period from 10 years before the index date to 30 days prior.

Medical conditions were assessed based on physician visits that occurred up to 30 days before the index date. The analysis used a curated list of approximately 200 common medical

conditions, compiled by the Leumit Research Institute and identified by their corresponding ICD-9 diagnosis codes or laboratory tests.

### Statistical analyses

Statistical analyses were performed in R version 4.4. Unless specified otherwise, Fisher's exact test was used to compare categorical variables and the two-tailed two samples t-test to compare continuous variables across groups. Conditional logistic models were fit to assess the association between SCZ group and covariates, such as medication consumption and diagnosis records across matched groups. Conditional logistic regression models were adjusted for age (years), gender, smoking status, SES category, number of past physician visits, previous pregnancy, and health worker status

### TriNetX cohort

Validation analyses were conducted using TriNetX, a global federated health research network that provides access to EHRs, including diagnoses, procedures, medications, laboratory values, and genomic information, from large healthcare organizations (HCOs). The validation studies were performed within the US Collaborative Network, which comprises 68 HCOs, and over 117 million patients.

We utilized the "compare outcomes" analysis framework, focusing on male individuals currently aged between 13 and 40 to ensure cohort homogeneity. Case individuals were defined as those who received the medication of interest between ages 10 and 30, while control individuals were those who had an ambulatory visit at the same age, which served as the index date in both groups.

To ensure balance at medication initiation date, propensity score matching (PSM) was applied based on age, ethnicity, race, BMI presence, and smoking status. SCZ occurrence was

compared between the two cohorts using a Cox proportional hazards model, with follow-up starting after the first occurrence of the index event. We did not limit the follow-up end time, and began it a day after the index date, except for the tramadol analysis, in which we began the analysis 2 years after medication uptake, to overcome a non-proportionality violation that occurred when the follow-up began earlier.

### Ethics Statement

The Institutional Review Board (IRB) of Leumit Health Services gave ethical approval for this work (LEU-0020-24), with a waiver of informed consent, since data were analyzed retrospectively and anonymously.

## Results

### The study cohort

Table 1 presents a demographic and clinical comparison of the SCZ and control patients from the LHS cohort at the index date. As expected from the matching procedure, the age and gender distributions were highly similar: in both groups, 76.1% were male, and the mean age was 24.2 ± 7.2 years. Clinical characteristics, which were not part of the matching criteria, also appeared largely comparable, with some notable differences: individuals with SCZ were significantly more likely to be smokers (Odds Ratio for current smoking: OR = 1.43, 95% CI [1.31–1.55]), a finding consistent with previous literature[13]. SCZ patients also had slightly higher diastolic blood pressure (72.1 ± 9.3 vs. 71.2 ± 9.2 mmHg, SMD = 0.098). Among the laboratory results, the most significant difference was observed in total Triiodothyronine (T3) levels (SMD = -0.409). A higher proportion of SCZ patients also had free T3 levels below 3.5 pmol/L (OR = 1.81 [1.17–2.74]), even though the reduction in free T3 was much less pronounced (SMD = -

0.049) than for total T3. Accordingly, significant differences were observed in Thyroid Stimulating Hormone (TSH) levels (SMD = 0.123), with a higher proportion of SCZ patients having TSH levels above 4.5 mIU/L, indicating subclinical hypothyroidism (OR = 2.00 [1.69–2.36]). Additional differences were noted in vitamin D levels (SMD = -0.137) and folic acid levels (SMD = -0.059), consistent with past observations[19–21]. Furthermore, SCZ patients were more likely to have folic acid levels below the deficiency threshold of 2.8 ng/mL (OR = 1.41 [1.20–1.64]) and vitamin D levels below the insufficiency threshold of 30 ng/mL (OR = 1.38 [1.18–1.61]).

### Medication use associated with the risk of SCZ occurrence

We investigated which classes of prior medication use were most associated with the risk of SCZ. For each medication classes present in our health system, we assessed their usage in both the SCZ and control groups over the 10 years preceding the index date. A significantly higher usage rate in the SCZ group compared to controls suggests that the medication may be associated with an increased risk of SCZ. Conversely, a significantly lower usage rate in the SCZ group may indicate a potential protective effect against SCZ occurrence.

Table 2 presents the medications with the most significant differences in past usage rates between the SCZ and control groups over the decade preceding the index date, categorized by therapeutic class. Statistical significance was assessed using Fisher's exact test, and only medications with a false discovery rate (FDR) below 10%, as calculated by the Benjamini-Hochberg (BH) procedure, were retained.

The greatest reduction in SCZ risk was observed with atovaquone/proguanil, a drug combination used for malaria prophylaxis (OR = 0.25 [0.07–0.67]). This medication combines a protozoal mitochondrial inhibitor with a dihydrofolate reductase (DHFR) inhibitor, disrupting

parasitic deoxythymidylate synthesis. The second largest reduction in SCZ risk was associated with the hepatitis A inactivated vaccine (OR = 0.32 [0.16–0.58]). Next, in order of risk reduction, are two ophthalmic antibiotic treatments: moxifloxacin (OR = 0.53 [0.32–0.84]) and a combination of oxytetracycline/polymyxin B (OR = 0.60 [0.40–0.87]). We also observed significant risk reductions with two topical antimicrobial treatments containing clindamycin: clindamycin/benzoyl peroxide (OR = 0.57 [0.41–0.78]) and clindamycin alone (OR = 0.76 [0.63–0.91]). A significant protective effect was also identified for aciclovir, an antiviral treatment for herpes (OR = 0.75 [0.63–0.88]). Conversely, a significant increase in risk was observed for a topical medication combining the antibiotic neomycin with hydrocortisone (OR = 1.42 [1.11–1.81]).

We also observed notable reductions in SCZ risk among individuals treated with certain oral antibiotics, notably phenoxymethylpenicillin (OR = 0.71[0.66–0.77]), amoxicillin/clavulanate (OR = 0.85 [0.79–0.92]), and azithromycin (OR = 0.84 [0.76 –0.92]).

Additionally, several nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with a significant decrease in SCZ risk, including the cyclooxygenase-2 (COX-2) inhibitor etoricoxib (OR = 0.74 [0.61–0.89]), the preferential COX-2 inhibitor etodolac (OR = 0.75 [0.63–0.88]) and ibuprofen (OR = 0.81 [0.75–0.87]). In contrast, the pain medication tramadol was associated with a significantly increased SCZ risk (OR = 1.42 [1.14–1.75]).

The greatest increase in SCZ risk was observed following treatment with desmopressin, a vasopressin analog used to treat nocturnal enuresis (OR = 1.48 [1.14–1.75]).

### Associations between past medical conditions and the risk of SCZ occurrence.

To assess medical conditions that could influence SCZ risk, we compared the prevalence of reported medical conditions between the two groups up to one month before the index date.

Table 3 displays 12 medical conditions that exhibited significant differences in reporting between the SCZ and control groups with an FDR below 1%, ranked by their odds ratio. We observe a significant decrease in SCZ risk among individuals diagnosed with infections of the upper respiratory tract, notably tonsillitis (OR = 0.75 [0.70–0.80]), sinusitis (OR = 0.77 [0.69–0.86]), and upper respiratory tract infections (URTI) (OR = 0.84 [0.78–0.90]). A significant decrease in SCZ risk was observed for individuals who were diagnosed with acne, a condition frequently treated with clindamycin. However, the risk reduction associated with acne diagnosis (OR = 0.84 [0.78–0.90]) was less pronounced than that observed for purchase of clindamycin-containing medications, suggesting that the risk reduction is primarily driven by these medications rather than by the acne condition itself.

Remarkably, past gastroenteritis was associated with a significantly reduced risk of SCZ (OR = 0.81 [0.75–0.88]), whereas constipation was associated with a significantly increased risk (OR = 1.37 [1.20–1.55]).

Significant increases in SCZ risk were observed among individuals diagnosed with attention deficit hyperactivity disorder (ADHD) (OR = 1.40 [1.26–1.55]), confirming previous findings[22] , and those with gingivitis (OR = 1.50 [1.24–1.81]). Three strong associations were found for three conditions linked to chronic liver damage: hepatitis C (OR = 2.30 [1.49–3.45]), hepatitis B (OR = 2.41 [1.66–3.43]), and alcoholism (OR = 4.87 [2.05–9.11]).

Finally, the most significant association was observed for glaucoma (OR = 4.46 [3.00–7.71]).

As with medication use, all identified associations correspond to conditions diagnosed well before SCZ onset, reinforcing the temporal precedence of these factors. To further account for residual differences between the two groups, we performed a multivariable regression analysis incorporating all identified medical conditions, adjusting for age, gender,

smoking status, socioeconomic status (SES), past physician visits, previous pregnancy, and health worker status.

Figure 1 presents a forest plot of the adjusted odds ratios and confidence intervals. All identified associations remained statistically significant after adjustment.

### Adjusted analysis of the impact of medications on the risk of SCZ

To further investigate the impact of past medication use on SCZ risk, we conducted an adjusted multivariable regression analysis, incorporating all medications previously identified as significantly associated with SCZ risk, along with potential confounding factors. In selected cases, we included in the regression medications from the same class or with similar therapeutic indications to determine whether the observed effects were attributable to broader therapeutic classes or could be confounded by overlapping medical indications.

Figure 2 presents a forest plot illustrating the results of the multivariable logistic regression analysis. The model is adjusted for age, gender, socioeconomic status (SES), smoking status, past pregnancy status, vaccination history, and the number of physician visits during the same period.

The strongest associations, observed for atovaquone/proguanil (adjusted OR (aOR) = 0.26 [0.09–0.70]) and the hepatitis A inactivated vaccine (aOR = 0.31 [0.17–0.57]), remained statistically significant in the adjusted model, with similar effect sizes. The two ophthalmic antimicrobial treatments previously identified as associated with decreased SCZ risk also remained highly protective: moxifloxacin drops (aOR = 0.53 [0.33–0.85]) and oxytetracycline/polymyxin B drops (aOR = 0.61 [0.42–0.89]).

To assess whether the observed association with SCZ risk might reflect differences in the prevalence of ophthalmic infections among individuals who later developed SCZ, we included

ophthalmic chloramphenicol, the most commonly prescribed treatment for eye infections in our health system and found it was not associated with any change in SCZ risk (aOR = 0.99 [0.88–1.10]), suggesting that the protective effect on SCZ risk is likely attributable to these two antibiotics rather than to the treated eye infection.

The reduction in SCZ risk observed among individuals who received topical clindamycin treatments remained significant for both clindamycin in combination with benzoyl peroxide (aOR = 0.59 [0.42–0.81]) and clindamycin alone (aOR = 0.78 [0.65–0.95]). To assess whether benzoyl peroxide alone could contribute to a reduction in SCZ risk, we included a variable for benzoyl peroxide-only preparations. After adjusting for other factors, we found that treatment with benzoyl peroxide alone was instead associated with an increased risk of SCZ (aOR = 1.28 [1.08–1.51]), suggesting that the protective effect observed for the combination of clindamycin and benzoyl peroxide is unlikely to be driven by benzoyl peroxide.

The increased risk associated with neomycin-based topical treatments remained significant in the multivariable regression analysis, both when neomycin was combined with clotrimazole and dexamethasone (aOR = 1.16 [1.04–1.30]) and when combined with hydrocortisone (aOR = 1.54 [1.21–1.96]). The stronger effect was observed with the ointment formulation, which has a greater ability to remain on the skin.

To assess whether the observed impact on SCZ risk could be attributed to the antifungal component clotrimazole, we included clotrimazole treatment as a variable in the multivariable regression model and found no significant association with SCZ risk. Similarly, to evaluate the potential contribution of the steroid component, we introduced mometasone, the most commonly prescribed medium-to-high potency corticosteroid, as a variable, and it was also not significantly associated with SCZ risk.

We also added to the regression commonly prescribed topical antibiotics, and found significant increase SCZ risk for most topical antibiotics, notably mupirocin (aOR = 1.16 [1.05–1.29]), gentamicin (aOR = 1.17 [1.01–1.36]), and fusidic acid (aOR = 1.24 [1.02–1.50]), with the highest risk observed for chloramphenicol (aOR = 1.25 [1.09–1.43]), a broad-spectrum antibiotic.

The protective association observed for aciclovir remained significant (aOR = 0.79 [0.67–0.94]), as did the protective effect of phenoxymethylpenicillin (aOR = 0.72 [0.66–0.79]) and amoxicillin/clavulanate (aOR = 0.86 [0.81–0.96]). The association for azithromycin remained borderline significant (aOR = 0.90 [0.82–1.00]).

The previously observed decrease in SCZ risk associated with NSAID treatment remained significant, notably for etoricoxib (aOR = 0.73 [0.60–0.90]), etodolac (aOR = 0.77 [0.65–0.92]), and ibuprofen (aOR = 0.84 [0.77–0.92]). Since the strongest effect was observed for etoricoxib, a COX-2 inhibitor, we assessed the effect of another COX-2 inhibitor, rofecoxib, and also observed a reduction in SCZ occurrence. However, due to the infrequent use of this medication, the statistical power was low, resulting in a wide confidence interval (aOR = 0.60 [0.34–1.03]) and borderline significance. As a control, we included in the regression analysis paracetamol, the most commonly used medication for pain and fever in our health system, and found no association with SCZ (aOR = 1.02 [0.94–1.11]). This suggests that the protective effect observed for SCZ is specific to NSAIDs and is not attributable to differences in the occurrence of pain or fever.

Conversely, pain medications containing tramadol were associated with a significant increase in SCZ risk, both when used alone (aOR = 1.62 [1.30–2.00]) and when combined with paracetamol (aOR = 1.50 [1.13–1.98]).

Finally, in the multivariable regression, desmopressin maintained a significant association with SCZ occurrence (aOR = 2.04 [1.49–2.80]).

### Validation in the US based trinetX collaborative network.

We further validated these associations using the U.S. TrinetX global network, which integrates EHRs from over 68 healthcare organizations and includes data on more than 117 million patients. Validation analyses were conducted for key medication associations identified in the LHS study.

Using TriNetX, we prospectively assessed the risk of SCZ associated with each medication by defining a cohort of individuals who initiated treatment between the ages of 10 and 30, and currently aged 30 to 40. This cohort was propensity score-matched to a control group selected from individuals undergoing ambulatory medical encounters, excluding those with a preexisting SCZ diagnosis from both groups. Cohorts were matched for age at index, gender, ethnicity, BMI, and tobacco use.

Results of these validation studies are summarized in Table 3. For atovaquone, we compared 29,911 patients who received atovaquone for the first time between ages 10 and 30 with 29,911 matched controls, selected from over 10 million patients who had an ambulatory medical visit at the same age. During follow-up, 37 patients (0.124%) in the atovaquone group developed SCZ, compared to 126 (0.421%) in the control group. A Cox proportional hazards model identified a hazard ratio (HR) of 0.29, 95% CI [0.20–0.42], further confirming its strong protective effect.

Using the same approach, we compared 181,671 patients who initiated topical clindamycin treatment with propensity-matched controls. The HR for SCZ after topical clindamycin treatment was 0.74 [0.66–0.83], further supporting clindamycin's protective effect.

Conversely, we examined 52,880 patients who initiated topical neomycin treatment with propensity-matched controls. The HR for SCZ following topical neomycin treatment was 2.00 [1.73–2.32], confirming an increased risk of SCZ associated with neomycin treatment.

We validated the impact of moxifloxacin drops by comparing 83,856 patients who received ophthalmic fluoroquinolone antibiotics (moxifloxacin, ciprofloxacin, ofloxacin, or levofloxacin) with matched controls. The HR for SCZ following ophthalmic fluoroquinolone treatment was 0.54 [0.45–0.63], indicating a reduced risk of SCZ after these treatments.

To validate the protective effect of COX-2 inhibitors, we assessed celecoxib, a commonly used COX-2 inhibitor in the U.S. We compared 54,081 patients who initiated celecoxib treatment with propensity-matched controls. The HR for SCZ following celecoxib treatment was 0.55 [0.45–0.67]. We also evaluated the non-exclusive COX-2 inhibitor etodolac, comparing 10,755 patients who initiated etodolac treatment with 10,755 propensity-matched controls. The HR for SCZ following etodolac treatment was 0.41 [0.28–0.60], suggesting preferential COX-2 inhibitors could have similar protective effect. Conversely, we assessed the effect of tramadol treatment on 215,543 patients who received tramadol with propensity-matched controls, and found a HR for SCZ following tramadol treatment was 1.24 [1.14–1.34].

Finally, we assessed the impact of desmopressin by comparing 40,745 patients who initiated desmopressin treatment with propensity-matched controls. To minimize potential indication bias, the presence of a diagnosis of nocturnal enuresis diagnosis was included in the propensity matching variables. The HR for SCZ following desmopressin treatment was 2.01 [1.59–2.54]. Owing to the large sizes of the cohorts, all p-values were highly significant ($P<0.0001$)

## Discussion

This report presents a large-scale, retrospective population study conducted within a national health provider over a 20-year period, analyzing 3,273 patients with SCZ and 32,730 matched controls. The findings reveal strong, statistically significant associations between past

medical treatments, diagnoses, laboratory tests and SCZ risk, providing new insights into key protective and risk-associated factors. The study's results were independently validated within the federated TriNetX US global network, which includes EHR data for over 117 million patients, using established analytical frameworks.

The most significant finding was that treatment with atovaquone/proguanil was associated with a dramatic decrease in SCZ risk for at least 10 years. Additionally, two clindamycin-based topical treatments also showed significant protective associations.

Further analysis identified strong protective associations with NSAIDs, with COX-2 inhibitors demonstrating a stronger effect. Interestingly, most of the medications linked to SCZ risk reduction were antibiotics, administered ophthalmologically, topically, or, in some cases, orally, suggesting that the implicated pathogens may reside or depend on colonization at sites affected by antibiotics administered via topical or ophthalmic routes.

Beyond medication exposure, we also identified significant associations between past medical conditions and SCZ risk, with diagnoses occurring up to 20 years before SCZ onset. Constipation, chronic liver diseases (including alcoholism, viral hepatitis B, and C), and glaucoma were associated with a significant increase in SCZ risk, whereas gastroenteritis and upper respiratory tract infections were associated with a reduced risk. These findings provide key insights into SCZ pathogenesis, shedding light on potential mechanisms underlying disease development.

Based on these observations, we propose what we believe to be the most plausible unifying hypothesis that explains the observed associations.

### Atovaquone/Proguanil and clindamycin

As shown in the multivariable medication analysis (Figure 2), the medication which uptake was associated with the strongest reduction in SCZ risk was atovaquone/proguanil (aOR = 0.26). We independently validated the reduction in SCZ occurrence following atovaquone use in the TriNetX U.S. cohort, which included 30,000 patients who received atovaquone and a PSM matched control group. We found a similar reduction in SCZ risk (HR = 0.29) with extremely strong statistical significance, yielding a p-value of less than 1 in 100 billion ($p<10^{-11}$).

In our health system, the primary indication for atovaquone/proguanil is malaria prophylaxis for individuals traveling to regions where malaria is endemic. Since malaria is not transmitted by local mosquitoes in Israel, atovaquone/proguanil is typically used for short-term prophylaxis in travelers or for the treatment of malaria in patients returning from affected countries.

Both atovaquone and proguanil target protozoan-specific metabolic pathways, which do not exist in human cells. Atovaquone inhibits the mitochondrial electron transport chain, while proguanil, through its active metabolite cycloguanil, inhibits dihydrofolate reductase (DHFR), thereby interfering with DNA synthesis. Since these mechanisms are specific to protozoa, any long-term protective effect of atovaquone/proguanil against SCZ is unlikely to be due to direct effects on human physiology. Therefore, the strong protective effect of atovaquone/proguanil against SCZ is most likely explained by its ability to target a protozoan pathogen involved in SCZ pathogenesis.

Strikingly, the presence of anti-*Toxoplasma gondii* antibodies - indicative of past infection - has been consistently identified as a significant risk factor for SCZ in multiple studies across different countries [23,24]. A 2012 meta-analysis of 38 studies conducted in 14 countries [12], encompassing 6,067 individuals with SCZ and 8,715 controls, reported an odds ratio (OR) of 2.71 [1.93–3.80] for *T. gondii* seropositivity in SCZ patients.

Given that *T. gondii* shares similar mitochondrial and folate metabolism pathways with other protozoa, atovaquone is effective against *T. gondii* and is sometimes used for toxoplasmosis treatment in patients who cannot tolerate sulfa-based therapies. However, while proguanil inhibits DHFR, which is also essential for *T. gondii* replication, pyrimethamine remains the standard DHFR inhibitor for toxoplasmosis treatment. Interestingly, the standard malaria prophylaxis regimen of 250 mg atovaquone once daily is much lower than the therapeutic dose for acute toxoplasmosis, which is 750 mg twice daily, often combined with clindamycin or with pyrimethamine and sulfadiazine for 4-6 weeks. The fact that even a low-dose, short-duration regimen appears to reduce SCZ risk suggests that even partial suppression or clearance of *T. gondii* may have long-term protective effects. Moreover, in the U.S. cohort, we found that extending the follow-up period beyond 10 years further enhanced the observed reduction in SCZ risk. This finding suggests that *T. gondii* may have a very long latency period in the human body before triggering symptoms characteristic of SCZ, providing a large window of opportunity for intervention and prevention.

*T. gondii* preferentially encysts in dopamine-rich brain regions, particularly the striatum and limbic areas, which regulate motivation, reward, and psychosis-related behaviors. Moreover, the parasite expresses a tyrosine hydroxylase-like enzyme, which converts tyrosine into L-DOPA, the precursor for dopamine. Chronically infected individuals are therefore expected to have elevated dopamine levels due to the parasite's ongoing production, but host compensation mechanisms, such as dopamine receptor downregulation, could mitigate the effect of this increase. Since atovaquone is highly effective against *T. gondii*, its rapid action may destroy cysts within days, potentially releasing large stores of intracellular dopamine previously contained within infected glial cells or neurons. The host, having adapted to chronic low-level increases in

dopamine, may fail to buffer the sudden surge, leading to dopaminergic overactivity and the onset of psychotic symptoms.

Such a manifestation was documented in a case report describing mania with psychotic symptoms in a young patient two days after receiving atovaquone/proguanil for malarial prophylaxis[25]. The timing of symptom onset, occurring two days post-treatment, aligns with the expected timeline for parasite clearance, suggesting a causal link. Additionally, the immune system's response to parasite destruction may increase cytokine activity in the brain, further altering dopamine regulation. Neuroinflammation has been implicated in psychotic exacerbations, particularly through microglial activation and elevated IL-6 and TNF-α, which can modulate dopamine turnover and receptor sensitivity.

Moreover, some of the antipsychotic medications commonly used to treat SCZ symptoms have demonstrated intrinsic anti-toxoplasmic properties, and it has been speculated that it may contribute to their therapeutic effects in patients with latent *T. gondii* infections[26].

Remarkably, clindamycin – an antimicrobial active against *T. gondii*[27] and recommended as an adjunctive treatment for toxoplasmosis [28] – was also identified in our study as negatively associated with SCZ occurrence, both alone and in combination with benzoyl peroxide. The observation that three medications showing significant protective associations against SCZ in our study have known activity against *T. gondii*, combined with the parasite's higher prevalence in SCZ patients, strongly supports the hypothesis that *T. gondii* may play a causal role in the disorder, with potential implications for both prevention and treatment.

In our cohort, we did not observe a strong reduction in SCZ occurrence among the few patients (~0.9%) who received oral clindamycin. This may be due to the fact that effective toxoplasmosis treatment requires prolonged therapy, whereas oral clindamycin used for common bacterial infections or for prophylaxis is typically prescribed for less than a week. Additionally,

clindamycin dosages for toxoplasmosis (600 mg every 6–8 hours) are significantly higher than those used for common bacterial infections (150–450 mg every 6–8 hours).

In contrast, topical clindamycin used for acne treatment is often administered over long periods, sometimes spanning years, meaning that even small doses given over extended durations could potentially impair *T. gondii* replication, delaying its ability to further colonize the host and possibly postponing SCZ onset.

Moreover, we hypothesize that the skin microbiome of the hands may serve as a primary vector for *T. gondii* transmission from the gut to the central nervous system (CNS). During the latency period, *T. gondii* replicating in the gastrointestinal tract may spread to the brain through self-inoculation via hand-to-eye or hand-to-mouth mucosal contact, mechanisms we will further explore in the following sections. When clindamycin is used topically, the hands applying it would be repeatedly exposed to the antibiotic, potentially eliminating any *T. gondii* parasites colonizing the hand microbiome on a daily basis.

### Topical antimicrobial medications and SCZ risk

In the multivariable medication analysis (Figure 2), we observed consistent and significant associations between topical antimicrobial treatments and SCZ risk. While topical clindamycin was associated with a decreased risk of SCZ, other topical antibiotics – including fusidic acid, chloramphenicol, gentamicin, and mupirocin – were linked to an increased risk. Notably, two neomycin-based compounds exhibited strong associations with increased SCZ risk, with adjusted odds ratios of 1.17 and 1.55, respectively. The strong increase of SCZ risk for neomycin was further confirmed in the TriNetX cohort, where 52,860 individuals who received topical neomycin had a risk for SCZ increased by a factor of 2.2 compared with their matched controls ($P<0.0001$).

These antibiotics are all likely to disrupt the commensal skin microbiota, which normally inhibits pathogen colonization, potentially creating niches for an opportunistic pathogen such as *Toxoplasma* to colonize the treated skin[29]. Remarkably, a recent study observed a persistent decrease in commensal Staphylococcus species, which play a role in protecting against pathogenic bacteria, following treatment with a neomycin-containing ointment[30]. In our analysis, the topical antibiotic associated with the highest observed increase in risk for SCZ was an ointment-based neomycin treatment, and the other neomycin compound, which had a milder effect, was in a cream formulation, that is expected to remain on the skin for a shorter duration.

Furthermore, poor social interactions have been frequently described in conditions associated with SCZ risk, such as schizotypal and schizoid personality disorders[2]. While skin-to-skin contacts with other humans may help restore normal skin microbiota[31], the avoidance of such contacts could potentially contribute to long-term disruptions in the skin flora, potentially creating conditions that may facilitate *T. gondii* persistence on the skin.

### Ophthalmic antimicrobial medications and SCZ risk

Our study identified two ophthalmic antibiotics specifically associated with a reduced risk of SCZ. Use of the fluoroquinolone moxifloxacin was associated with a 47% reduction in SCZ risk (aOR = 0.53), while an oxytetracycline-based compound (unavailable in the U.S.) had a milder protective effect (aOR = 0.61). We validated this finding in the TriNetX cohort, where treatment with ophthalmic fluoroquinolones across 46,592 patients showed a similar risk reduction (HR = 0.54, P<0.0001) compared to their matched controls.

Fluoroquinolones exert their antimicrobial effects by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication. Interestingly, studies suggest that they may also interfere with *T. gondii* replication by either targeting the apicoplast, a plastid

crucial for parasite survival, or disrupting mitochondrial function, thereby impairing parasite proliferation[32,33]. A similar inhibitory effect of *T. gondii* was also observed for oxytetracycline[34], which inhibits the apicoplast 30S ribosomal unit, blocking translation.

The strong susceptibility of the SCZ-associated pathogen to ophthalmic antibiotics suggests that the eye may serve as a gateway for the pathogen to reach the brain and/or that it resides in the nasal cavity or paranasal sinuses, where ophthalmic antibiotics could accumulate via lacrimal duct drainage. Remarkably, *T. gondii* is known to infect the eye, causing ocular toxoplasmosis[35], which typically manifests as retinochoroiditis, the leading cause of posterior uveitis worldwide.

Further supporting this hypothesis is our finding that glaucoma was the most significant medical condition associated with SCZ occurrence (aOR = 4.51), a finding consistent with previous studies[36]. Here, this association was evident even before SCZ diagnosis, suggesting that glaucoma and SCZ may share a common risk factor. While excessive ocular pressure is the usual mechanism underlying optic nerve degeneration in glaucoma, its early onset preceding SCZ suggests an alternative pathway, possibly involving direct *T. gondii* insult to the optic nerve.

### Oral and upper respiratory medical conditions and SCZ risk

In the past medical conditions forest plot (Figure 1) shows that medical conditions that trigger an increased immune response in the upper respiratory system are associated with a reduced risk of SCZ, particularly sinusitis (aOR = 0.76), tonsillitis (aOR = 0.84), and upper respiratory tract infections (aOR = 0.87).

A common trait of these infections is that they induce a strong localized immune response, including increased secretion of secretory IgA, activation of macrophages and neutrophils, and upregulation of pro-inflammatory cytokines, all of which may help eliminate *T.*

*gondii* from the oronasal mucosa. Additionally, pathogen competition and microbiome alterations caused by bacterial and viral infections could create an unfavorable environment for *T. gondii* adherence and invasion. Frequent epithelial turnover due to inflammatory damage may further prevent parasite persistence, while increased mucus secretion and ciliary clearance could physically remove *T. gondii* from the mucosal surface.

Conversely, we identified that gingivitis was significantly associated with increased SCZ risk (aOR = 1.59). Gingivitis is a condition characterized by inflammation of the gingiva caused by pathogens residing in dental plaque. Gingivitis could both facilitate *T. gondii* infection by weakening the oral mucosal barrier and serve as an indicator of underlying oral toxoplasmosis, especially in individuals with recurrent or severe periodontal disease.

Moreover, periodontal inflammation may also promote the recruitment of monocytes and macrophages, which *T. gondii* can use as Trojan horses for dissemination to other tissues, including the brain.

Interestingly, our study identified a protective effect for three antibiotics effective against oral bacteria involved in gingivitis and periodontal infections: phenoxymethylpenicillin (aOR = 0.72), amoxicillin/clavulanate (aOR = 0.86), and azithromycin (aOR = 0.91). Elimination of pathogenic bacteria from oral and upper respiratory sites may explain how they might contribute to reduced risk of SCZ.

Remarkably, a high prevalence of smoking has been consistently observed among patients developing SCZ[13], including in our study (OR = 1.43). Smoking involves frequent contact between the hand and the oral mucosa, which may facilitate pathogen transmission between these sites. Additionally, cannabis use has been identified as a risk factor for psychosis in multiple studies[14]. However, we did not observe an increased SCZ risk among patients receiving medical cannabinoids, including prescribed smoked formulations. This suggests that the risk associated

with cannabis use may be more behavioral than pharmacological, potentially linked to the frequent hand-to-mouth contact involved in rolling and sealing joints, which provides a continuous route for hand-borne pathogens to reach the oral mucosa.

Last, the observed decrease in SCZ risk following treatment with topical aciclovir (aOR = 0.80), a nucleoside analog that specifically targets herpes simplex virus (HSV) by inhibiting viral DNA replication, suggests that a herpesvirus may play a role in the dissemination of *T, gondii*. Indeed, if a cell co-infected with both HSV and *T. gondii* undergoes HSV-induced apoptosis, this would release intracellular *T. gondii* tachyzoites into the extracellular environment, thus facilitating invasion of neighboring cells or dissemination to distant tissues.

## The gastrointestinal tract and SCZ risk

The multivariable regression analysis for medications, as shown in the forest plot (Figure 2), identified two gastrointestinal transit disorders as significantly affecting SCZ risk in opposite directions, strongly suggesting a role for the gut in SCZ pathogenesis: constipation was associated with a notable increase in SCZ risk (aOR = 1.54), whereas gastroenteritis was linked to a significant risk reduction (aOR = 0.83).

The gut may provide a more favorable environment for *T. gondii* replication than the CNS or skin. In the CNS, neurons – being terminally differentiated cells with low turnover rates – create a stable environment that favors the parasite's transition into the bradyzoite latent state within tissue cysts, minimizing immune detection and limiting active replication. In the skin, *T. gondii* encounters physical and immune barriers, as well as low metabolic activity and limited cell turnover, further restricting its invasion and proliferation potential.

In contrast, the intestinal epithelium undergoes continuous and rapid renewal, with enterocytes being replaced approximately every 4 to 5 days. This high turnover rate provides *T.*

*gondii* with ample opportunities to invade new cells, sustaining its replication cycles. Consequently, the primary route for *T. gondii* infection is through enterocytes in the small intestine, where the parasite can replicate, as tachyzoites, before disseminating to other tissues. Furthermore, the gut-associated lymphoid tissue (GALT) in the colon is designed to tolerate a wide range of antigens, including commensal microbiota, while maintaining immune homeostasis. This tolerogenic environment may allow *T. gondii* to evade immediate immune detection, facilitating its persistence and replication within intestinal cells. Additionally, the presence of immune cells in the lamina propria can aid in the parasite's systemic dissemination once it breaches the epithelial barrier.

Altered intestinal transit may further influence *T. gondii* replication and persistence. Reduced intestinal motility, such as in constipation, may provide an even more favorable environment by prolonging parasite contact with the intestinal epithelium, enhancing invasion and replication within enterocytes. Slow transit may also promote microbial fermentation and gut microbiome alterations that reduce immune surveillance, supporting local parasite persistence, explaining the increased risk observed in constipation.

In contrast, gastroenteritis is associated with increased intestinal transit, limiting the time available for *T. gondii* tachyzoites or bradyzoites to attach to and invade host cells. Moreover, increased peristalsis and rapid fluid loss may further facilitate the physical expulsion of parasites from the gut, potentially explaining how gastroenteritis reduces SCZ risk.

### Impaired liver function and SCZ risk

The past medical conditions forest plot (Figure 1) shows that three of the four most significant risk factors for SCZ occurrence are related to liver dysfunction: alcoholism (aOR = 3.85), hepatitis C (aOR = 2.15), and hepatitis B (aOR = 2.33), consistent with previous

findings[37,38], but here demonstrated to predate SCZ diagnosis. In addition, after atovaquone, the medication most strongly associated with a decreased SCZ risk was the hepatitis A vaccine (aOR = 0.31). This vaccine, which was added to Israel's routine immunization program for toddlers in 1999[39], protects against a common cause of liver dysfunction in young individuals. While most hepatitis A cases resolve within three months, liver function abnormalities can persist for up to six months in some individuals. Additionally, 60% of hepatitis A infections in children and 30% in adults are mild or subclinical, detectable only by a transient elevation in liver enzymes, without clinical symptoms.

Further evidence of impaired liver function in SCZ patients is reflected in the disproportionate reduction in total T3 levels compared to free T3 levels. The decrease in total T3 levels in SCZ patients (1.78 ± 0.42 vs. 2.00 ± 0.54, SMD = -0.409) is an order of magnitude greater than the reduction observed in free T3 levels (4.92 ± 1.33 vs. 4.99 ± 1.27, SMD = -0.049). The difference between total T3 and free T3 levels reflects the fraction bound to thyroid-binding globulin (TBG), a protein synthesized in the liver. Since TBG production depends on hepatic function, its reduction is a well-recognized marker of liver dysfunction, indicating impaired hepatic protein synthesis.

The liver is a key organ in immune surveillance and pathogen clearance, playing a crucial role in preventing the systemic spread of *T. gondii*. It serves as a primary filter for pathogens entering through the bloodstream and orchestrates both innate and adaptive immune responses. Liver dysfunction can compromise these protective mechanisms, allowing *T. gondii* to disseminate more effectively. In healthy individuals, the liver acts as a critical barrier by capturing and eliminating parasites through Kupffer cells, NK cells, and T-cell activation. Additionally, the liver produces key complement proteins that enhance immune recognition and

clearance of *T. gondii*. However, in liver dysfunction, complement production declines, weakening the host's ability to control infection.

Furthermore, the liver synthesizes acute-phase proteins and cytokines (IL-6, TNF-α, IFN-γ) that regulate immune responses. IFN-γ is particularly critical in controlling *T. gondii* replication, and reduced hepatic cytokine production can lead to increased parasite survival.

Therefore, liver dysfunction –- whether induced by chronic alcoholism, hepatitis A, hepatitis B, or hepatitis C – and reflected by low TBG levels, suggests a compromised ability to contain *T. gondii* within the liver, facilitating its systemic dissemination. This underscores the importance of liver health in preventing the spread of *T. gondii* and suggests that impaired liver function may contribute to increased susceptibility to toxoplasmosis-related complications, including neuroinflammation and potential links to SCZ.

### NSAIDs are associated with reduced SCZ risk

In our study, we found significant negative associations between treatment with several nonsteroidal anti-inflammatory drugs (NSAIDs), notably etoricoxib (aOR = 0.73), etodolac (aOR = 0.73), ibuprofen (aOR = 0.77), and the risk of developing SCZ. We further confirmed this association in the TriNetX database, comparing 46,592 patients who initiated celecoxib treatment with an equal number of propensity-matched controls, and find a strong reduction of SCZ risk following celecoxib treatment (HR=0.46, $P < 0.0001$), further supporting a protective effect of COX-2 inhibitors.

Neuroinflammation has been strongly implicated in SCZ pathogenesis[40], with evidence of elevated pro-inflammatory cytokines (e.g., interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta) and microglial activation in the brains of SCZ patients[41]. NSAIDs, particularly selective COX-2 inhibitors, may reduce SCZ risk by mitigating neuroinflammation. COX-2 expression has

been found to be elevated in the brains of SCZ patients[42]. Interestingly, studies have shown that adjunctive NSAID treatment, particularly with COX-2 inhibitors, can improve psychotic symptoms in some SCZ patients, suggesting an anti-inflammatory therapeutic benefit[43]. Moreover, increased microglial activation in SCZ leads to excessive synaptic pruning and neuronal damage[41]. NSAIDs may suppress microglial activation, potentially preserving synaptic integrity and preventing the neuronal loss associated with SCZ. Neuroinflammation may also contribute to blood-brain barrier (BBB) dysfunction[44] , potentially allowing *T. gondii* to enter the brain, possibly via peripheral immune cells. *T. gondii* is known to exploit monocytes and dendritic cells to cross the BBB using a "Trojan Horse" mechanism. NSAIDs may help stabilize the BBB[45], thereby preventing *T. gondii* invasion, reducing neuronal damage, and mitigating further inflammation.

## Tramadol increases SCZ risk

In contrast to NSAIDs, we found that treatment with tramadol, a weak opioid used for pain management, was significantly associated with an increased SCZ risk (aOR = 1.50 for combined forms with paracetamol and 1.62 for tramadol alone). We confirmed this increased risk by following 205,943 patients who received tramadol versus a matched control group in the TriNetX cohort (HR = 1.24). The increased risk associated with this medical opioid aligns with previous studies that have linked opioid use disorder (OUD) to an elevated risk of SCZ progression[46].

Consistent with our hypothesis regarding *T. gondii* replication in the gut, the slowing effect of tramadol on intestinal peristalsis could create a more favorable environment for parasite replication by increasing its contact time with the intestinal epithelium. Additionally, opioids

suppress immune function, and reduced immune surveillance may allow higher *T. gondii* loads in the CNS, exacerbating inflammation and neuronal damage.

Moreover, opioids have been shown to increase blood-brain barrier (BBB) permeability by disrupting tight junction proteins, potentially facilitating the entry of *T. gondii* tachyzoites into the brain and accelerating cyst formation. Lastly, opioids exacerbate neuroinflammation and glial cell dysregulation, which may contribute to worsening neuropsychiatric symptoms.

These findings underscore the need for cautious opioid prescribing and vigilant monitoring among young patients at risk for developing SCZ.

### Vasopressin and SCZ risk

The medication associated with the most significant increase in SCZ risk in our analysis was desmopressin (aOR = 2.04), a synthetic vasopressin analog commonly prescribed for nocturnal enuresis. This association may be partially explained by the increased incidence of nocturnal enuresis as an early symptom preceding SCZ[47]. However, this does not appear to be the sole explanation, as the association with desmopressin was stronger than the association observed with a nocturnal enuresis diagnosis.

To further investigate this relationship, we conducted a validation study in TriNetX, comparing 38,866 patients who initiated desmopressin treatment with an equal number of propensity-matched controls. In this analysis, we accounted for nocturnal enuresis diagnosis by including it as a variable in the propensity-matching process. Despite this adjustment, the HR for SCZ following desmopressin treatment remained significantly elevated (HR = 2.01, $P<0.0001$).

Interestingly, vasopressin-related genes have been significantly associated with SCZ in gene linkage studies [48], suggesting a potential role for vasopressin dysregulation in SCZ pathogenesis. Additionally, gene expression analyses have shown upregulation of both the

vasopressin (AVP) gene and its receptor (AVPR1a) in SCZ patients, further supporting the hypothesis that increased vasopressin system activation may contribute to SCZ development [49].

Moreover, AVP influences BBB permeability and immune cell trafficking, potentially facilitating *T. gondii* neuroinvasion and cyst formation, which may contribute to SCZ development. Additionally, AVP overstimulation triggers microglial activation, leading to chronic neuroinflammation and neurotransmitter dysregulation, both of which are implicated in SCZ pathogenesis.

Therefore, caution should be exercised when prescribing AVP agonists to individuals at risk for SCZ.

### Laboratory tests and SCZ risk

In our comparison of cohorts at the index date (Table 1), we observed significantly reduced levels of free T3, vitamin D and folic acid in individuals who developed SCZ compared to the controls.

Notably, SCZ patients were significantly more likely to have T3 deficiency, with free T3 levels below 3.5 pmol/L (OR = 1.8). Correspondingly, a higher proportion of SCZ patients had TSH levels above 4.5 mIU/L (OR = 2.0), suggesting subclinical or clinical hypothyroidism.

Thyroid hormones play a central role in both immune function and brain homeostasis. T3 regulates microglial activity, and lower T3 levels may impair microglial-mediated pathogen clearance, reducing the ability to control infections in the brain. Additionally, T3 modulates blood-brain barrier (BBB) integrity, and lower levels may increase BBB permeability, potentially facilitating the neuroinvasion of *T. gondii* and contributing to SCZ pathogenesis.

SCZ patients of our cohort were also more likely to have vitamin D insufficiency, with levels below 30 ng/mL (OR = 1.38), consistent with previous studies[50]. Vitamin D plays a critical

role in the immune response, particularly in antimicrobial defense mechanisms[51–53]. It promotes innate immunity by stimulating macrophages and dendritic cells to produce cathelicidin and defensins, which have direct antiparasitic activity against *T. gondii*. Low vitamin D levels impair IFN-γ production, a cytokine essential for controlling *T. gondii* replication in the brain and other tissues. Studies have linked low vitamin D levels with increased susceptibility to chronic infections, including *T. gondii*, which may contribute to its persistence in SCZ patients.[54,55]

SCZ patients in our cohort also had a higher prevalence of folic acid deficiency (OR = 1.41). Folic acid deficiency impairs host immune responses, increasing vulnerability to *T. gondii* through several mechanisms. Folic acid is essential for DNA synthesis and immune cell proliferation, particularly in T-cell–mediated immunity, which plays a critical role in controlling intracellular pathogens like *T. gondii*. Additionally, low folate levels may impair microglial function, reducing their ability to eliminate intracellular parasites and increasing the risk of persistent infection.

## Conclusion

This large-scale, retrospective, population-based study, conducted within a national health provider over a 20-year period, identified statistically significant associations between past medical treatments and medical history, offering new insights into potential protective and risk-associated factors for SCZ. Key findings were validated in the TriNetX global U.S. network, which includes over 117 million patients, strengthening the generalizability of our results.

Consistent with previous evidence of high *Toxoplasma gondii* seropositivity in SCZ patients, our findings revealed a very significant reduction in SCZ risk following treatment with atovaquone and clindamycin, two antimicrobial agents known to effectively eliminate *T. gondii*.

This strongly suggests a causal link between toxoplasmosis and SCZ, as risk reduction persisted for over a decade post-treatment in both Israeli and American cohorts.

Additionally, our analysis identified NSAIDs consumption, particularly those with strong COX-2 inhibition, as strongly associated with a reduced risk of SCZ, reinforcing the role of neuroinflammation in disease pathogenesis and suggesting a potential therapeutic role for NSAIDs in SCZ management.

These findings offer important insights into SCZ pathogenesis and open new avenues for future research. While causality cannot be definitively established, the consistent temporal relationships across two distinct large cohorts provide compelling support for the involvement of *T. gondii* in SCZ pathogenesis. We propose a unifying hypothesis that integrates these associations, suggesting that chronic *T. gondii* infection, enabled by immune dysregulation, impaired liver function, microbiota alterations, and neuroinflammation may converge as key drivers of SCZ development.

Future studies investigating the presence of *T. gondii* in stool, hand skin, periodontal pockets, oronasal and eye secretions could help validate its role in SCZ pathogenesis. Our findings suggest that a controlled elimination strategy of *T. gondii* – such as combining atovaquone with COX-2 inhibitors and dopamine-stabilizing agents like atypical antipsychotics – may represent a promising therapeutic approach with the potential to improve outcomes for individuals with *T. gondii* and psychotic symptoms. We encourage the development of randomized controlled trials to rigorously test and validate this hypothesis.

## References and Notes


1. Solmi, M. *et al.* Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. *Mol Psychiatry* **28**, 5319–5327 (2023).
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM), Edition (5th*. (2013).
3. Solmi, M. *et al.* Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol Psychiatry* **27**, 281–295 (2022).
4. Harvey, P. D., Strassnig, M. T. & Silberstein, J. Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. *J Exp Psychopathol* **10**, (2019).
5. Li, P., Snyder, G. L. & Vanover, K. E. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. *Curr Top Med Chem* **16**, 3385–3403 (2016).
6. Haddad, P. M. & Correll, C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. *Ther Adv Psychopharmacol* **8**, 303–318 (2018).
7. Haddad, P., Brain, C. & Scott, J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. *Patient Relat Outcome Meas* 43 (2014) doi:10.2147/PROM.S42735.
8. Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4. *Nature* **530**, 177–183 (2016).
9. Pers, T. H. *et al.* Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes. *Hum Mol Genet* **25**, 1247–1254 (2016).

10. Hilker, R. *et al*. Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. *Biol Psychiatry* **83**, 492–498 (2018).

11. Vassos, E., Pedersen, C. B., Murray, R. M., Collier, D. A. & Lewis, C. M. Meta-Analysis of the Association of Urbanicity With Schizophrenia. *Schizophr Bull* **38**, 1118–1123 (2012).

12. Torrey, E. F., Bartko, J. J. & Yolken, R. H. Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update. *Schizophr Bull* **38**, 642–647 (2012).

13. de Leon, J. & Diaz, F. J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophr Res* **76**, 135–157 (2005).

14. Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. & Vassos, E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. *Schizophr Bull* **42**, 1262–1269 (2016).

15. Stilo, S. A. & Murray, R. M. Non-Genetic Factors in Schizophrenia. *Curr Psychiatry Rep* **21**, 100 (2019).

16. Gilmore, J. H., Fredrik Jarskog, L., Vadlamudi, S. & Lauder, J. M. Prenatal Infection and Risk for Schizophrenia: IL-1β, IL-6, and TNFα Inhibit Cortical Neuron Dendrite Development. *Neuropsychopharmacology* **29**, 1221–1229 (2004).

17. Lee, Y. H. *et al.* Maternal Bacterial Infection During Pregnancy and Offspring Risk of Psychotic Disorders: Variation by Severity of Infection and Offspring Sex. *American Journal of Psychiatry* **177**, 66–75 (2020).

18. Nielsen, P. R., Benros, Michael. E. & Mortensen, P. B. Hospital Contacts With Infection and Risk of Schizophrenia: A Population-Based Cohort Study With Linkage of Danish National Registers. *Schizophr Bull* **40**, 1526–1532 (2014).

19. Firth, J. *et al.* Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis. *Schizophr Bull* **44**, 1275–1292 (2018).

20. Gurholt, T. P. *et al.* Vitamin D, Folate and the Intracranial Volume in Schizophrenia and Bipolar Disorder and Healthy Controls. *Sci Rep* **8**, 10817 (2018).

21. Misiak, B. *et al.* Thyroid hormones in persons with schizophrenia: A systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* **111**, 110402 (2021).

22. Cheng, N. *et al.* The Prevalence of Attention Deficit Hyperactivity Disorder in Psychotic Disorders: Systematic Review and Meta-analysis. *Schizophr Bull* (2025) doi:10.1093/schbul/sbae228.

23. Cetinkaya, Z., Yazar, S., Gecici, O. & Namli, M. N. Anti-Toxoplasma gondii Antibodies in Patients With Schizophrenia--Preliminary Findings in a Turkish Sample. *Schizophr Bull* **33**, 789–791 (2007).

24. Sutterland, A. L. *et al.* Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta□analysis. *Acta Psychiatr Scand* **132**, 161–179 (2015).

25. Romão Franco, A. M., Machado Nogueira, J., Jesus, G. & Cotta, C. Mania With Psychotic Symptoms After Malaria Prophylaxis With Atovaquone-Proguanil. *J Clin Psychopharmacol* **42**, 331–333 (2022).

26. Fond, G. *et al.* Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. *Eur Arch Psychiatry Clin Neurosci* **264**, 179–183 (2014).

27. Pfefferkorn, E. R., Nothnagel, R. F. & Borotz, S. E. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. *Antimicrob Agents Chemother* **36**, 1091–1096 (1992).

28. Wei, H.-X., Wei, S.-S., Lindsay, D. S. & Peng, H.-J. A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans. *PLoS One* **10**, e0138204 (2015).

29. Leyva, W. H. & Santa Cruz, D. J. Cutaneous toxoplasmosis. *J Am Acad Dermatol* **14**, 600–605 (1986).

30. SanMiguel, A. J., Meisel, J. S., Horwinski, J., Zheng, Q. & Grice, E. A. Topical Antimicrobial Treatments Can Elicit Shifts to Resident Skin Bacterial Communities and Reduce Colonization by Staphylococcus aureus Competitors. *Antimicrob Agents Chemother* **61**, (2017).

31. Eckermann, H. A., Meijer, J., Cooijmans, K., Lahti, L. & de Weerth, C. Daily skin-to-skin contact alters microbiota development in healthy full-term infants. *Gut Microbes* **16**, (2024).

32. Gozalbes, R. *et al.* Anti- *Toxoplasma* Activities of 24 Quinolones and Fluoroquinolones In Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Techniques. *Antimicrob Agents Chemother* **44**, 2771–2776 (2000).

33. Khan, A. A., Araujo, F. G., Brighty, K. E., Gootz, T. D. & Remington, J. S. Anti-*Toxoplasma gondii* Activities and Structure-Activity Relationships of Novel Fluoroquinolones Related to Trovafloxacin. *Antimicrob Agents Chemother* **43**, 1783–1787 (1999).

34. Perea, E. J. & Daza, R. M. The effect of minocycline, doxycycline and oxytetracycline on experimental mouse toxoplasmosis. *Bull Soc Pathol Exot Filiales* **69**, 367–72 (1976).

35. Park, Y.-H. & Nam, H.-W. Clinical Features and Treatment of Ocular Toxoplasmosis. *Korean J Parasitol* **51**, 393–399 (2013).

36. Liu, C.-H. *et al.* Association of ocular diseases with schizophrenia, bipolar disorder, and major depressive disorder: a retrospective case-control, population-based study. *BMC Psychiatry* **20**, 486 (2020).

37. Lv, M. *et al.* Alcohol drinking in male patients with chronic schizophrenia: prevalence and its relationship to clinical symptoms. *Front Psychiatry* **14**, (2023).

38. Lluch, E. & Miller, B. J. Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis. *Gen Hosp Psychiatry* **61**, 41–46 (2019).

39. Dagan, R. Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers. *JAMA* **294**, 202 (2005).

40. Müller, N., Weidinger, E., Leitner, B. & Schwarz, M. J. The role of inflammation in schizophrenia. *Front Neurosci* **9**, (2015).

41. Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4. *Nature* **530**, 177–183 (2016).

42. Minghetti, L. Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases. *J Neuropathol Exp Neurol* **63**, 901–910 (2004).

43. Sommer, I. E. *et al.* Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. *Schizophr Bull* **40**, 181–191 (2014).

44. Najjar, S., Pearlman, D. M., Alper, K., Najjar, A. & Devinsky, O. Neuroinflammation and psychiatric illness. *J Neuroinflammation* **10**, 43 (2013).

45. Candelario-Jalil, E., Yang, Y. & Rosenberg, G. A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. *Neuroscience* **158**, 983–994 (2009).

46. Li, K. J., Chen, A. & DeLisi, L. E. Opioid use and schizophrenia. *Curr Opin Psychiatry* **33**, 219–224 (2020).

47. Hyde, T. M. *et al*. Enuresis as a premorbid developmental marker of schizophrenia. *Brain* **131**, 2489–2498 (2008).

48. Teltsh, O. *et al*. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. *International Journal of Neuropsychopharmacology* **15**, 309–319 (2012).

49. Broniarczyk-Czarniak, M., Szemraj, J., Śmigielski, J. & Gałecki, P. The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia. *Curr Issues Mol Biol* **44**, 336–349 (2022).

50. Cui, X., McGrath, J. J., Burne, T. H. J. & Eyles, D. W. Vitamin D and schizophrenia: 20 years on. *Mol Psychiatry* **26**, 2708–2720 (2021).

51. Schwalfenberg, G. K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. *Mol Nutr Food Res* **55**, 96–108 (2011).

52. Martens, P.-J., Gysemans, C., Verstuyf, A. & Mathieu, A. C. Vitamin D's Effect on Immune Function. *Nutrients* **12**, (2020).

53. Lagishetty, V., Liu, N. Q. & Hewison, M. Vitamin D metabolism and innate immunity. *Mol Cell Endocrinol* **347**, 97–105 (2011).

54. Huang, J., Wu, Y., Wang, M., Zhu, Y. & Lin, S. Lower Vitamin D Levels are Associated with Higher Seroprevalence of Toxoplasma gondii—a US National Survey Study. *Zoonoses* **2**, (2022).

55. Rasheed, Z. *et al*. Toxoplasmosis in immunocompetent Saudi women: Correlation with vitamin D. *Women's Health* **17**, (2021).

56. Israel, A. *et al*. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *The BMJ* **375**, e067873 (2021).

**Funding:** This study was funded internally by Leumit Health Services.

**Author contributions:**

Conceptualization: AI, EMe, EMa

Methodology: AI, EMe

Investigation: AI, SI, JS, EMe

Writing – original draft: AI

Writing – review & editing: AI, AW, SI, JS, SA, SV, EMa, EMe

**Competing interests:** Authors declare that they have no competing interests.

**Materials & Correspondence:** Correspondence and requests for materials should be addressed to AI

**Abbreviations**:

ADHD: Attention deficit hyperactivity disorder

AVP: Vasopressin

AVPR1a: Vasopressin receptor 1A

aOR: adjusted Odds Ratio

BMI: Body Mass Index

BP: Blood pressure

CNS: Central nervous system

COX-2: Cyclooxygenase-2

EHR: Electronic health records

FDR: False Discovery Rate

HCO: Healthcare organizations

HR: Hazards Ratio

ICD-9: International Classification of Diseases, Ninth Revision

IM: Intramuscular

LHS: Leumit Health Services

OR: Odds Ratio

PO: Per os

PSM: Propensity score matching

SCZ: Schizophrenia

SES: Socioeconomic status

SMD: Standardized Mean Difference

T3: Triiodothyronine

TBG: Thyroid-binding globulin

TSH: Thyroid-stimulating hormone

URTI: Upper Respiratory Tract Infection

**Table 1. Demographic and clinical characteristics of the study cohort at index date**

| | | SCZ N=3,273 | Control N=32,730 | P-value | Odds Ratio | SMD |
|---|---|---|---|---|---|---|
| Gender | Female | 782 (23.9 %) | 7,820 (23.9 %) | 1.000 | 1 | |
| | Male | 2,491 (76.1 %) | 24,910 (76.1 %) | 1.000 | 1 | |
| Age (years) | | 24.2 ± 7.2 | 24.2 ± 7.2 | 0.979 | | 0.001 |
| Age category | 10-18 | 914 (27.93 %) | 8,978 (27.43 %) | 0.983 | 1.03 [0.95–1.11] | |
| | 19-29 | 1,537 (46.96 %) | 15,495 (47.34 %) | 0.985 | 0.98 [0.92–1.06] | |
| | 30-39 | 772 (25.1%) | 7,749 (25.2 %) | 0.931 | 1.00 [0.91–1.08] | |
| | 40 | 50 (1.53 %) | 508 (1.55 %) | 1.000 | 0.98 [0.72–1.32] | |
| Weight (kg) | | 68.1 ± 19.1 | 68.4 ± 19.3 | 0.511 | | -0.012 |
| | missing | 73 (2.23 %) | 2,280 (6.97 %) | | | |
| Height (cm) | | 168 ± 12 | 168 ± 13 | 0.041 | | -0.038 |
| | missing | 122 (3.73 %) | 3,248 (9.92 %) | | | |
| Body Mass Index (kg/m2) | | 24.0 ± 5.6 | 24.0 ± 5.4 | 0.857 | | 0.003 |
| | missing | 110 (3.36 %) | 3,007 (9.19 %) | | | |
| BP systolic (mmHg) | | 117 ± 17 | 117 ± 14 | 0.004 | | 0.055 |
| | missing | 171 (5.22 %) | 2,595 (7.93 %) | | | |
| BP diastolic (mmHg) | | 72.1 ± 9.3 | 71.2 ± 9.2 | <0.001 | | 0.098 |
| | missing | 171 (5.22 %) | 2,611 (7.98 %) | | | |
| Smoking status | Non-smoker | 2,040 (67.93 %) | 20,893 (74.67 %) | <0.001 | 0.72 [0.66–0.78] | |
| | Past smoker | 23 (0.77 %) | 316 (1.13 %) | 0.079 | 0.68 [0.42–1.03] | |
| | Smoker | 940 (31.30 %) | 6,771 (24.20 %) | <0.001 | 1.43 [1.31–1.55] | |
| | missing | 270 (8.25 %) | 4,750 (14.51 %) | <0.001 | 0.53 [0.46–0.60] | |
| eGFR MDRD (mL/min/1.73m2) | | 129 ± 48 | 130 ± 56 | 0.422 | | -0.017 |
| | missing | 809 (24.7 %) | 9,689 (29.6 %) | | | |
| Glucose (mg/dL) | | 88.5 ± 16.0 | 88.4 ± 14.7 | 0.705 | | 0.080 |
| | missing | 919 (28.1 %) | 10,572 (32.3 %) | | | |
| Total T3 (triiodothyronine) (nmol/L) | | 1.78 ± 0.42 | 2.00 ± 0.54 | <0.001 | | -0.409 |
| | < 1.2 nmol/L | 15 (4.04 %) | 34 (1.44 %) | 0.002 | 2.88 [1.44–5.51] | |
| | missing | 2,902 (88.7 %) | 30,367 (92.8 %) | | | |
| Free T3 (pmol/L) | | 4.92 ± 1.33 | 4.99 ± 1.27 | 0.036 | | -0.049 |
| | < 3.5 pmol/L | 13 (3.77 %) | 111 (2.12 %) | 0.006 | 1.81 [1.17–2.24] | |
| | missing | 2,451 (74.9 %) | 27,496 (84.0 %) | | | |
| TSH (Thyroid Stimulating Hormone) (mIU/L) | | 2.30 ± 2.26 | 2.05 ± 2.02 | <0.001 | | 0.123 |
| | > 4.5 mIU/L | 187 (6.15 %) | 872 (3.17 %) | <0.001 | 2.00 [1.69–2.36] | |
| | missing | 234 (7.15 %) | 5,195 (15.87 %) | | | |
| Vitamin D (ng/mL) | | 18.9 ± 8.9 | 20.1 ± 9.1 | <0.001 | | -0.137 |
| | < 30 ng/mL | 1,935 (90.29 %) | 14,939 (87.11 %) | <0.001 | 1.38 [1.18–1.61] | |
| | missing | 1,130 (34.5 %) | 15,581 (47.6 %) | | | |
| Folic Acid (ng/mL) | | 6.61 ± 3.85 | 6.83 ± 3.70 | <0.001 | | -0.059 |
| | < 2.8 ng/mL | 217 (9.22 %) | 1,254 (6.74 %) | <0.001 | 1.41 [1.20–1.64] | |
| | missing | 920 (28.1 %) | 14,120 (43.1 %) | | | |

SMD: Standardized Mean Difference (Cohen's D)

**Table 2. Comparison of medication purchases in the 10 years to 30 days before the index date in the SCZ and control groups**

| ATC code | ATC description | SCZ N=3273 | Control N=32,730 | Odds Ratio | 95% Confidence Interval | P-value | FDR |
|---|---|---|---|---|---|---|---|
| P01BB51 | Atovaquone + Proguanil (PO) | 4 (0.122%) | 161 (0.491%) | ↓ 0.25 | [0.07–0.67] | 0.000989 | 0.020 |
| J07BC02 | Hepatitis A, Inactivated vaccine (IM) | 11 (0.336%) | 341 (1.042%) | ↓ 0.32 | [0.16–0.58] | 0.002700 | 0.046 |
| S01AE07 | Moxifloxacin (ophthalmic) | 19 (0.581%) | 356 (1.088%) | ↓ 0.53 | [0.32–0.84] | 0.004919 | 0.070 |
| S01AA20 | Oxytetracycline + Polymyxin B (ophthalmic) | 30 (0.917%) | 494 (1.509%) | ↓ 0.60 | [0.40–0.87] | 0.005701 | 0.080 |
| D10AF51 | Clindamycin/Benzoyl peroxide (topical) | 42 (1.283%) | 727 (2.221%) | ↓ 0.57 | [0.41–0.78] | 0.000223 | 0.005 |
| D10AF01 | Clindamycin (topical) | 136 (4.155%) | 1762 (5.383%) | ↓ 0.76 | [0.63–0.91] | 0.002376 | 0.041 |
| D07CA01 | Neomycin + Hydrocortisone (topical) | 81 (2.475%) | 573 (1.751%) | ↑ 1.42 | [1.11–1.81] | 0.004756 | 0.069 |
| D06BB03 | Aciclovir (topical) | 163 (4.980%) | 2151 (6.572%) | ↓ 0.75 | [0.63–0.88] | 0.000285 | 0.006 |
| J01CE02 | Phenoxymethylpenicillin (PO) | 885 (27.039%) | 11193 (34.198%) | ↓ 0.71 | [0.66–0.77] | $4.49 \cdot 10^{-17}$ | <0.001 |
| J01CR02 | Amoxicillin and Clavulanate (PO) | 1096 (33.486%) | 12152 (37.128%) | ↓ 0.85 | [0.79–0.92] | $3.69 \cdot 10^{-5}$ | 0.001 |
| J01FA10 | Azithromycin (PO) | 556 (16.987%) | 6442 (19.682%) | ↓ 0.84 | [0.76–0.92] | 0.000174 | 0.004 |
| M01AH05 | Etoricoxib (PO) | 122 (3.727%) | 1635 (4.995%) | ↓ 0.74 | [0.61–0.89] | 0.001039 | 0.021 |
| M01AB08 | Etodolac (PO) | 162 (4.950%) | 2125 (6.493%) | ↓ 0.75 | [0.63–0.88] | 0.000407 | 0.009 |
| M01AE01 | Ibuprofen (PO) | 1010 (30.859%) | 11638 (35.558%) | ↓ 0.81 | [0.75–0.87] | $6.70 \cdot 10^{-8}$ | <0.001 |
| N02BE51 | Tramadol (PO) | 105 (3.208%) | 748 (2.285%) | ↑ 1.42 | [1.14–1.75] | 0.001382 | 0.025 |
| H01BA02 | Desmopressin (PO) | 70 (2.139%) | 475 (1.451%) | ↑ 1.48 | [1.13–1.92] | 0.003311 | 0.055 |

ATC: Anatomical Therapeutic Chemical Classification System; PO: Per Os; FDR: False Discovery Rate
Medications purchased only in the 30 days preceding the index date were excluded
Odds ratio and P-values were computed according to Fisher's exact tests performed on the matched cohort

**Table 3. Comparison of diagnoses presence in the 20 years preceding the index date in the schizophrenia (SCZ) and control groups**

| Diagnosis group | SCZ N=3273 | Control N=32,730 | Odds Ratio | 95% Confidence Interval | P-value | FDR |
|---|---|---|---|---|---|---|
| TONSILLITIS | 1,433 (43.8 %) | 16,697 (51.0 %) | ↓ 0.75 | [0.70–0.80] | $2.96 \cdot 10^{-15}$ | <0.001 |
| SINUSITIS | 387 (11.8 %) | 4,872 (14.9 %) | ↓ 0.77 | [0.68–0.86] | $1.36 \cdot 10^{-6}$ | <0.001 |
| GASTROENTERITIS | 920 (28.1 %) | 10,656 (32.6 %) | ↓ 0.81 | [0.75–0.88] | $1.58 \cdot 10^{-7}$ | <0.001 |
| URTI | 1,937 (59.2 %) | 20,747 (63.4 %) | ↓ 0.84 | [0.78–0.90] | $2.47 \cdot 10^{-6}$ | <0.001 |
| ACNE | 616 (18.8 %) | 7,075 (21.6 %) | ↓ 0.84 | [0.77–0.92] | 0.0002 | <0.001 |
| CONSTIPATION | 296 (9.04 %) | 2,221 (6.79 %) | ↑ 1.37 | [1.20–1.55] | $3.38 \cdot 10^{-6}$ | <0.001 |
| ADHD | 506 (15.46 %) | 3,778 (11.54 %) | ↑ 1.40 | [1.26–1.55] | $1.75 \cdot 10^{-10}$ | <0.001 |
| GINGIVITIS | 137 (4.19 %) | 925 (2.83 %) | ↑ 1.50 | [1.24–1.81] | $2.87 \cdot 10^{-5}$ | <0.001 |
| HEPATITIS C | 30 (0.92 %) | 131 (0.40 %) | ↑ 2.30 | [1.49–3.45] | 0.00015 | <0.001 |
| HEPATITIS B | 40 (1.22 %) | 167 (0.51 %) | ↑ 2.41 | [1.66–3.43] | $4.55 \cdot 10^{-6}$ | <0.001 |
| GLAUCOMA | 12 (0.367 %) | 27 (0.082 %) | ↑ 4.46 | [2.05–9.11] | 0.0001 | 0.003 |
| ALCOHOLISM | 29 (0.886 %) | 60 (0.183 %) | ↑ 4.87 | [3.00–7.71] | $4.55 \cdot 10^{-10}$ | 0.007 |

FDR: False Discovery Rate
Diagnoses added only in the 30 days preceding the index date were excluded
Odds ratio and P-values were computed according to Fisher's exact tests performed on the matched cohort

**Table 4. Validation studies in TriNetX U.S. cohort**

| Group treated | Group control | N treated | N matched | Hazards Ratio | 95% Confidence Interval | P-value |
|---|---|---|---|---|---|---|
| Atovaquone | ambulatory visit | 29,911 | 29,847 | ↓ 0.29 | [0.20–0.42] | $3.5 \cdot 10^{-12}$ |
| Clindamycin (topical) | ambulatory visit | 178,165 | 176,719 | ↓ 0.74 | [0.66–0.83] | $3.1 \cdot 10^{-7}$ |
| Neomycin (topical) | ambulatory visit | 52,880 | 52,860 | ↑ 2.00 | [1.73–2.32] | $2.3 \cdot 10^{-21}$ |
| Fluoroquinolone (ophthalmic) | ambulatory visit | 83,856 | 83,551 | ↓ 0.54 | [0.45–0.63] | $8.7 \cdot 10^{-14}$ |
| Celecoxib | ambulatory visit | 54,081 | 53,711 | ↓ 0.55 | [0.45–0.67] | $2.5 \cdot 10^{-9}$ |
| Etodolac | ambulatory visit | 10,755 | 10,631 | ↓ 0.41 | [0.28–0.60] | $1.5 \cdot 10^{-6}$ |
| Tramadol | ambulatory visit | 215,543 | 214,642 | ↑ 1.24 | [1.14–1.34] | $7.6 \cdot 10^{-8}$ |
| Desmopressin | ambulatory visit (no AVP) | 40,715 | 38,795 | ↑ 2.01 | [1.59–2.54] | $3.0 \cdot 10^{-9}$ |

Medications were tested on a cohort of healthcare organizations (HCOs) within the TriNetX US Collaborative Network, which includes 68 HCOs and a total of 117 million patients. We selected male patients who are currently between 13 and 40 years old and who underwent treatment between the ages of 10 and 30. The index date was defined as the first ambulatory visit occurring at or after medication uptake for the treatment group, or any ambulatory visit for the control group.
Patients with a prior diagnosis of schizophrenia (SCZ) before the index date were excluded.
Groups were matched using propensity scores, accounting for age, ethnicity, race, smoking status, BMI presence, and, for the desmopressin validation, the presence of nocturnal enuresis.

**Figure 1: Forest plot of schizophrenia (SCZ) risk according to medical conditions documented in the 20 years preceding the index date**




The conditional logistic regression model included all the listed medical conditions is adjusted for age (years), gender, smoking status, SES category, number of past physician visits, previous pregnancy, and health worker status

aOR: Adjusted Odds Ratio; URTI: Upper Respiratory Tract Infection; ADHD: Attention Deficit Hyperactivity Disorder

**Figure 2: Forest plot of schizophrenia risk according to medication purchase history in the 10 years preceding the index date**




The multivariable conditional logistic regression model included all the listed medications and is adjusted for age (years), gender, smoking status, SES category, number of past physician visits, previous pregnancy, and health worker status

aOR: Adjusted Odds Ratio; PO: Per Os; IM: Intramuscular


diagnosis recorded
at least once before the index date
Multivariable
aOR [95% CI]
P value
TONSILLITIS
0.76 [0.70 to 0.82]
< 0.0001
GASTROENTERITIS
0.83 [0.76 to 0.91]
< 0.0001
SINUSITIS
0.84 [0.75 to 0.94]
0.0026
URTI
0.87 [0.80 to 0.94]
0.0010
ADHD
1.54 [1.37 to 1.72]
< 0.0001
CONSTIPATION
1.54 [1.35 to 1.76]
< 0.0001
GINGIVITIS
1.59 [1.31 to 1.92]
< 0.0001
HEPATITIS C
2.15 [1.38 to 3.34]
0.0007
HEPATITIS B
2.33 [1.61 to 3.37]
< 0.0001
ALCOHOLISM
3.85 [2.42 to 6.13]
< 0.0001
GLAUCOMA
4.51 [2.17 to 9.38]
< 0.0001
decreased SCZ
increased SCZ
.125
.25
.5
1
2
4
8
16


Medication purchased
at least once in the 10 years preceding the index date
Multivariable
aOR [95% CI]
P value
Atovaquone + Proguanil (PO) 0.26 [0.09 to 0.70] 0.0080
Hepatitis A, inactivated vaccine (IM) 0.31 [0.17 to 0.57] 0.0002
Moxifloxacin (ophthalmic) 0.53 [0.33 to 0.85] 0.0078
Oxytetracycline + Polymyxin B (ophthalmic) 0.61 [0.42 to 0.89] 0.0099
Chloramphenicol (ophthalmic) 0.98 [0.88 to 1.10] 0.7823
Clindamycin + Benzoyl peroxide (topical) 0.59 [0.42 to 0.81] 0.0012
Clindamycin (topical) 0.78 [0.65 to 0.94] 0.0102
Benzoyl Peroxide (topical) 1.28 [1.08 to 1.51] 0.0043
Neomycin + Clotrimazole + Dexamethasone (topical) 1.16 [1.04 to 1.30] 0.0081
Neomycin + Hydrocortisone ointment (topical) 1.54 [1.21 to 1.96] 0.0005
Clotrimazole (topical) 1.06 [0.94 to 1.21] 0.3382
Mometasone (topical) 1.12 [0.96 to 1.31] 0.1542
Mupirocin (topical) 1.16 [1.05 to 1.29] 0.0041
Gentamicin (topical) 1.17 [1.01 to 1.36] 0.0334
Fusidic Acid (topical) 1.24 [1.02 to 1.50] 0.0324
Chloramphenicol (topical) 1.25 [1.09 to 1.43] 0.0017
Aciclovir (topical) 0.79 [0.67 to 0.94] 0.0074
Phenoxymethylpenicillin (PO) 0.72 [0.66 to 0.79] < 0.0001
Amoxicllin + Clavulanate (PO) 0.86 [0.79 to 0.93] 0.0003
Azithromycin (PO) 0.90 [0.82 to 1.00] 0.0519
Rofecoxib (PO) 0.60 [0.34 to 1.03] 0.0659
Etoricoxib (PO) 0.73 [0.60 to 0.90] 0.0027
Etodolac (PO) 0.77 [0.65 to 0.92] 0.0036
Ibuprofen (PO) 0.84 [0.77 to 0.92] 0.0001
Paracetamol (PO) 1.02 [0.94 to 1.11] 0.6274
Tramadol + Paracetamol (PO) 1.50 [1.13 to 1.98] 0.0052
Tramadol (PO) 1.62 [1.30 to 2.03] < 0.0001
Desmopressin (PO) 2.04 [1.49 to 2.80] < 0.0001
decreased SCZ
increased SCZ
.125
.25
.5
1
2
4
8